logo

Incyte Corporation (INCY)



Trade INCY now with
  Date
  Headline
9/30/2021 6:03:38 AM Lilly Announces Detailed Results From Two Pivotal Phase 3 Trials Of BRAVE-AA1 And BRAVE-AA2 For Alopecia Areata
9/27/2021 6:02:33 AM Syndax Pharma, Incyte Enters Exclusive Worldwide Collaboration And License Agreement To Develop Axatilimab
9/22/2021 1:01:14 PM Incyte Announces FDA Approval Of Jakafi For Treatment Of Chronic Graft-Versus-Host Disease
8/24/2021 8:32:19 AM Incyte: Health Canada Approves Minjuvi In Combination With Lenalidomide For R/r Diffuse Large B-Cell Lymphoma
8/17/2021 4:23:32 AM Incyte Announces Commercialization Agreement With InnoCare For Tafasitamab In Greater China
8/3/2021 7:32:38 AM Incyte Corporation (INCY) Has Lowered Its FY21 EPS Estimate To 2125 - 2170 From 2125 - 2200
8/3/2021 7:09:28 AM Incyte Q2 GAAP EPS $0.67; Non-GAAP EPS $0.80
8/3/2021 6:05:06 AM Eli Lilly, Incyte Announce Results From Additional Cohort Of 101 Adult Patients From COV-BARRIER Trial